Cansino Biologics Inc.'s financial report for the six months ended June 30, 2024 shows a significant increase in revenue compared to the same period last year, but still records an operational loss. The loss during the period is mainly due to an increase in the cost of goods sold. In addition, the company lost control over its subsidiary Cansino, reclassifying it as an affiliated company. The company also faces a lawsuit in Brazil, but management believes it is unlikely to be required to pay any economic compensation. As of June 30, 2024, the company's primary operational assets are mainly located in mainland China and Hong Kong.

Cansino Biologics Inc.'s financial report for the six months ended June 30, 2024 shows a significant increase in revenue compared to the same period last year, but still records an operational loss. The loss during the period is mainly due to an increase in the cost of goods sold. In addition, the company lost control over its subsidiary Cansino, reclassifying it as an affiliated company. The company also faces a lawsuit in Brazil, but management believes it is unlikely to be required to pay any economic compensation. As of June 30, 2024, the company's primary operational assets are mainly located in mainland China and Hong Kong.